Stay up to date with the latest news and insights on fighting aging and age-related diseases by subscribing to Fight Aging! This newsletter is dedicated to the goal of using modern medicine to control the mechanisms of aging and ultimately end age-related diseases. Join thousands of subscribers who are interested in this important mission.
If you are looking to dive deeper into the longevity industry, consider consulting with Reason, the founder of Fight Aging! and Repair Biotechnologies. He offers strategic consulting services to investors, entrepreneurs, and anyone interested in the complexities of the longevity industry. Learn more about his services here: https://www.fightaging.org/services/
In our recent newsletter, we discussed the correlation between cardiometabolic disease and accelerated brain aging. It is well-established that conditions such as type 2 diabetes and heart disease can contribute to the onset and progression of neurodegenerative diseases. This association highlights the importance of addressing the underlying damage processes that lead to age-related diseases. Individuals with one form of age-related disease are at a higher risk of developing other related conditions, emphasizing the interconnected nature of these health issues.
Research has shown that the presence of cardiometabolic disease is not only linked to dementia but also to cognitive decline, changes in brain structure, and other early signs of aging in the brain. Understanding these connections is crucial for developing effective interventions to promote healthy brain aging.
The TAME Trial for Metformin, aimed at targeting aging as a medical condition, has faced challenges in securing full funding. While the FDA approved the trial design, funding remains a hurdle, partly due to the choice of metformin as the treatment. Metformin’s efficacy in slowing aging is still a topic of debate, with some suggesting that other treatments like rapamycin may be more promising. The completion of the TAME trial will shed light on the potential of metformin in combating age-related diseases.
To stay updated on these and more topics related to fighting aging, visit our newsletter archives here: https://www.fightaging.org/newsletter/
If you are interested in supporting the TAME trial or learning more about its progress, visit this link: https://www.fightaging.org/archives/2024/04/the-tame-trial-for-metformin-remains-only-partially-funded/
Join us in the fight against aging and age-related diseases, and help shape the future of longevity research and interventions. Subscribe to Fight Aging! today.
